key: cord-0874591-hh806aeb
authors: Alqahtani, Fulwah Yahya; Aleanizy, Fadilah Sfouq; Mohamed, Rania Ali El Hadi; Al-Maflehi, Nassr; Alrfaei, Bahauddeen M; Almangour, Thamer A; Alkhudair, Nora; Bawazeer, Ghada; Shamlan, Ghalia; Alanazi, Marzouqah S
title: Association Between Obesity and COVID-19 Disease Severity in Saudi Population
date: 2022-05-16
journal: Diabetes Metab Syndr Obes
DOI: 10.2147/dmso.s365491
sha: d51c0fb011c3f3245c57d81b018be49aa8c2c801
doc_id: 874591
cord_uid: hh806aeb

BACKGROUND: The persistent coronavirus disease 2019 (COVID-19) outbreak has placed a significant burden on the scientific and medical professions. The study examined the association between body mass index (BMI), stratified by category, and severe form of COVID-19, and to explore the influence of demographic characteristics and other known risk factors. METHODS: This was a retrospective analysis based on COVID-19 data from the Saudi Arabian Ministry of Health. Data were collected for all patients admitted to three main hospitals in Riyadh region between March 1st and July 30, 2020. The effects of BMI, demographic characteristics, clinical presentation, and comorbidities on infection severity were investigated. RESULTS: A total of 950 patients were included in the study (70% male, 85% aged younger than 60 years old). A total of 55 (5.8%) patients were underweight, 263 (27.7%) were normal weight, 351 (37%) were overweight, 161 (17%) were obese class I, 76 (8%) were obese class II, and 44 (4.6%) were obese class III. Cough, fever, and shortness of breath were the most common symptoms among overweight patients. According to the findings of a bivariate logistic regression study, class III obesity was significantly associated with a more severe form of COVID-19 (odds ratio, 2.874; 95% confidence interval, 1.344–6.149). CONCLUSION: This study revealed that patients with a BMI ≥40 kg/m(2) had a higher risk of severe COVID-19 than those with normal weight. This suggests that obesity is a risk factor for severe COVID-19 and influences disease presentation.

In March 2019, the World Health Organization declared the latest pandemic in human history caused by a novel strain of coronavirus. 1 As of December 25, 2021, the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), officially known as COVID-19, infected more than 279 million cases with over 5,395,856 deaths. 2 Approximately 14% of patients admitted with COVID-19 developed severe pneumonia and meet the criteria for acute respiratory distress syndrome. 3 Several factors have been linked to COVID-19 disease severity and mortality. These include advanced age; male sex; and comorbid diabetes mellitus, cardiovascular disease, respiratory disease, kidney, and liver disorders. 4, 5 Obesity also emerged as one of the risk factors linked to unfavorable disease course and was a significant contributor to poor health outcomes, including higher incidence of ICU admissions and need for mechanical ventilation. [6] [7] [8] Patients with body mass index (BMI) ≥30 kg/m 2 represent a substantial proportion of hospitalized patients with COVID-19. 2 Two other studies found that obesity was a risk factor for invasive mechanical ventilation. 9 ,10 A case control study of 179,288 patients admitted in the periods before the pandemic 11, 12 (149,098 patients) and (30, 190 patients) during the pandemic found that patients with BMI >40kg/m 2 has higher odds for increased mortality during the COVID-19 compared to pre-pandemic odds. 13 Pre-dating the COVID-19 era, the association between obesity and markers of inflammation is well established. Indeed, during the 2009 H1N1 influenza pandemic obese patients had twice the risk of admission to ICU and death. 14 Moreover, the main characteristics observed in severe COVID-19 is the overwhelming triggering of the body inflammatory responses with dysregulation of innate and adaptive immunity. 15 Likewise, there is a wealth of literature describing the role of inflammatory, immunological and coagulopathic processes in obese patients leading to increased risk of cardiometabolic diseases, severity of illnesses and hospitalization. 16 Hence, for obese patient, a coinfection with COVID-19 infection is a double whammy 17-19 independent of the age and comorbidities. 20 Recent literatures with data from various countries highlighted the severity of illness in COVID-19 in obese individuals [21] [22] [23] [24] in different population and ethnicity. Conversely, several studies demonstrated no difference in disease severity in obese patients. 25 In Saudi Arabia, the country recorded 552,406 COVID-19 cases, with 8870 deaths. 2 Obesity was reported to be prevalent in 35.6% of Saudi individuals according to a national survey done between 1995 and 2000. 26 In 2013, nationwide research revealed a prevalence rate of 28.7%. 27 However, to the best of our knowledge, a limited number of national studies has investigated the association between obesity and COVID-19. Therefore, this study aims to characterize the association between BMI, stratified by category, and the severe form of COVID-19, and to investigate interactions with demographic characteristics and other known risk factors.

This is a retrospective study utilizing Ministry of Health databases linked to three main hospitals in Riyadh region. Patients with COVID-19 admitted from March 1, 2020 to July 30, 2020 were included in this study. The Institutional Review Board of the Ministry of Health approved the study protocol and methodology (IRB-20222E-RC20.239.R). Informed consent was obtained from all patients before participating in the study. The study was conducted in accordance with the hospital management guidelines and MoH regulations. Our research was in compliance with the Helsinki Declaration.

The demographics, clinical presentations, comorbidities, BMI, severity, and outcome of COVID-19 were obtained and recorded. All patients have documentation of COVID-19 diagnosis using nucleic acid test (real-time reverse transcriptase polymerase chain reaction assay [RT-PCR] for SARS-CoV-2). 28 Parent or legal guardian of patients under 18 years of age provided informed consent. Patients were stratified into different groups according to BMI as follows: underweight (≤18.5 kg/m 2 ), normal (18.5-24.9 kg/m 2 ), overweight (25.0-29.9 kg/m 2 ), class I obesity (30-34.9 kg/m 2 ), class II obesity (35-39.9 kg/m 2 ), and class III obesity (≥40 kg/m 2 ). 29 For COVID-19 disease severity classification, WHO guidance on COVID-19 guidance was adopted. 30 The absence of clinical symptoms of COVID-19 infections with a positive RT-PCR result was defined as asymptomatic infections. Mild COVID-19 illness was defined as the absence of respiratory distress and imaging indications of pneumonia, as well as the presence of mild clinical symptoms. Moderate disease was defined as observable fever, respiratory symptoms, and pneumonia on CT. Severe disease was defined as the presence of at least one of the following three conditions: respiratory distress, a respiratory rate equal to or more than 30 beats per minute, oxygen saturation in the resting state ≤93%, or arterial blood oxygen partial pressure/oxygen concentration ≤300 mmHg (1 mmHg = 0.133 kPa). Critical illness was defined as when patients had respiratory failure requiring mechanical ventilation, shock, or combined organ failure necessitating intensive care unit (ICU) monitoring and treatment.

Descriptive statistics were utilized, and significance was assessed using the chi-squared test and parametric or nonparametric binomial tests when appropriate, and multivariate binary logistic regression was used to determine the https://doi.org/10.2147/DMSO.S365491

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2022:15 association of obesity with severe or critical COVID-19 patients' disease. Statistical analyses were performed using IBM SPSS version 25 software (IBM Corp., Armonk, NY, USA). The level of significance was set at 0.05 for all tests (P < 0.05).

A total of 951 patients were diagnosed with COVID-19 between March 1 and July 30, 2020. Table 1 shows the demographic and clinical features of patients stratified by the BMI standard classification. Men accounted for 70% (664) and Saudi Nationals accounted for 53% (498) of the cases. BMI significantly increased with age from 21 to 60 years (p < 0.05). BMI distribution was as follows: overweight (351, 37%), class I obesity (161, 17%), class II obesity (76, 8%), and class III obesity (44, 4 .6%). The majority of patients with COVID-19 patients had mild disease (602, 63%); 167 (17.6%) had moderate disease, 102 (10.7%) had severe disease, and only 63 (6.6%) were classified as critically ill (Table 1) . Notably, BMI was significantly higher in patients with severe and critical disease (p < 0.05).

The most prevalent symptoms among patients with COVID-19 were fever, cough, and shortness of breath, and these symptoms were significantly associated with overweight patients (p < 0.05) ( Table 2 ). A total of 3.8% of patients were asymptomatic.

Diabetes mellitus was found in 20% of patients with COVID-19, hypertension in 10%, immunocompromise in 5.4%, chronic kidney disease in 4.3%, asthma in 4.23%, and coronary heart disease in 3% (Table 3) . A significant association was observed between diabetes mellitus and chronic liver disease in overweight patients (p < 0.05). Almost 2.5% of patients had travelled abroad before getting infected, while 20% of patients were in contact with positive cases. Management protocol employed and patient outcomes are summarized in Table 4 . Antibiotics, bronchodilators, antimalaria, and corticosteroids were prescribed in 30%, 24.6%, 6.6%, and 2.5% of cases, respectively (Table 4 ). These medications were administered significantly more to overweight patients. Symptom's improvement was seen in 45% of the cases with an average hospital stay of 10.02 ± 5.91 days and 2% of patients died from COVID-19 and they were all critical cases. The results of the bivariate logistic regression analysis are demonstrated in Table 5 ; class III obesity (odds ratio [OR] = 2.874; 95% confidence interval [CI], 1.344-6.149) and diabetes mellitus (OR = 5.385; 95% CI, 3.622-8.005) were significantly and independently associated (p < 0.05) with severe COVID-19.

The focus of this study was to characterize the relationship between BMI, stratified by category, and severity of COVID-19, as well as to explore the interplay between demographic parameters and other recognized risk factors. In consistent with other studies, our findings demonstrated that overweight and obese patients were more likely to present with symptomatic disease with history of fever, cough, and shortness of breath. 31 The multivariable analysis conducted in our study showed that the severity of COVID-19 increased significantly in patients with a BMI ≥40 kg/m 2 . This is consistent with the earlier findings of others in which patients with BMI >35 kg/m 2 were found to require mechanical ventilation more than those with BMI <25 kg/m 2 . 9, 32, 33 The association between obesity and worse outcomes in patients with COVID-19 is expected. Thus, obese patients are associated with rapid progression of the disease. Similar findings were observed in obese patients who were infected with H1N1, a novel influenza A strain that emerged in 2009, and their weight had affected their risk of hospitalization, mechanical ventilation, and death, regardless of their other comorbidities. 34, 35 Pulmonary complications are known to be more common in obese patients because of upper respiratory illnesses caused by a reduction in lung volume, hypoventilation, congestive heart failure, and acute respiratory distress syndrome. 36 Moreover, recent studies have shown that COVID-19 infection leads to a hypercoagulable state, hence, elevated risk of pulmonary embolism, stroke, and arterial thrombosis. 37 Furthermore, a systemic inflammatory response initiated by the activation of CD4+ T lymphocytes into T-helper 1 cells that produce cytokines is thought to contribute to the adverse respiratory outcomes observed in COVID-19 patients. This leads to massive production of inflammatory cytokines, causing a cytokine storm that results in apoptosis, vascular leakage, poor virus clearance, altered tissue homeostasis, acute lung injury, cardiac dysfunction, and subsequent acute respiratory distress syndrome. 38 been reported in patients with severe COVID-19. 40 In patients with obesity, there is chronic subclinical inflammation, which includes an increase in the same inflammatory markers that are involved in cytokine storm. 41, 42 In obesity, both hypercoagulable and hyperinflammatory states exist, which may increase the risk of COVID-19 infection severity. 

Alterations in immunological function, particularly complement activation, thrombosis likelihood, and alterations in lung function are all possible causes of a worsened disease course in obese patients. An earlier study reported that obese patients, in comparison to those with normal weight, have altered immune cell activity. 43 Such disturbances in host defense in obese patients could increase the risk of COVID-19 complications. The observed inflammation, platelet activation, and endothelial dysfunction observed in COVID-19 increase the risk of thrombotic illness in both the venous and arterial circulation. 44 Thrombotic diseases, such as pulmonary embolism, are regarded as another manifestation of severe disease that contributes to the need for ICU admission and an increase in mortality, although it was not investigated in our study. As reported in a previous report, 45 obesity is associated with a higher risk of thrombosis due to increased platelet activation and increased production of prothrombotic factors. This prothrombotic condition may predispose obese patients with COVID-19 to thrombotic incidents, which are associated with greater disease severity and poor prognosis. 46 Having a high BMI has adverse consequences on lung function, lowering the forced expiratory volume and forced vital capacity. 47 The ability of a patient to sustain adequate oxygenation is directly affected by changes in the respiratory mechanics. This might explain the higher rate of cough and shortness of breath observed in our study in overweight patients than in patients with normal BMI.

In the current study, the prevalence of cardiometabolic disorders such as diabetes, hypertension, and coronary artery disease did not increase as BMI increased. However, diabetes mellitus was found to be associated with severe COVID-19, as revealed by multivariable regression analysis conducted in our study, which corroborates previous findings. [48] [49] [50] This implies that these diseases contribute to poor COVID-19 outcomes, regardless of BMI.

Limitations of the study include the retrospective nature of this study and the limited number of patients included. Other factors may contribute to the severity of COVID-19 in obese patients, which could become significant in future studies involving larger sample sizes. Moreover, due to the small number of deaths recorded in our study, we were unable to investigate the effect of BMI on death rates.

In conclusion, the results of the current study collectively revealed that the severity of COVID-19 was significantly higher in patients with a BMI ≥40 kg/m 2 . This study highlights obesity as a serious health problem, particularly regarding its association with severe COVID-19 infection and emphasizes the importance of addressing obesity as a public health issue in Saudi Arabia.

COVID-19-new insights on a rapidly changing epidemic

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area

Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics and risk factors of patients with severe COVID-19 in Riyadh, Saudi Arabia: a retrospective study

Risk of COVID-19 for patients with obesity

A systematic review and meta-analysis of obesity and COVID-19 outcomes

Obesity aggravates COVID-19: an updated systematic review and meta-analysis

High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Prevalence of obesity among adult inpatients with COVID-19 in France

Obesity a predictor of outcomes of COVID-19 hospitalized patients-A systematic review and meta-analysis

Obesity increases the severity and mortality of influenza and COVID-19: a systematic review and meta-analysis

Obesity as a mortality risk factor in the medical ward: a case control study

Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis

Biomarkers in COVID-19: an up-to-date review. Front Pediatr

Markers of chronic inflammation in overweight and obese individuals and the role of gender: a Cross-Sectional Study of a large cohort

The effect of obesity on lung function

Management of acute respiratory distress syndrome in obese patients

The weight of obesity in immunity from influenza to COVID-19

Obesity predisposes to the risk of higher mortality in young COVID-19 patients

Association between obesity and diabetes prevalence and COVID-19 mortality in Mexico: an Ecological study

The association between obesity and severity in patients with coronavirus disease 2019: a retrospective, single-center study, Wuhan

Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 cardiovascular disease registry

Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients

Obesity in Saudi Arabia

28. World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases

WHO Consultation on Obesity, World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation

World Health Organization. Clinical Management of COVID-19: Interim Guidance. Geneva: World Health Organization

Clinical manifestations of COVID-19 differ by age and obesity status

Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission

Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York city

Obesity and pro-inflammatory mediators are associated with acute kidney injury in patients with A/H1N1 influenza and acute respiratory distress syndrome

Hospitalized patients with 2009 H1N1 influenza infection: the Mayo Clinic experience

Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease

Thrombosis in hospitalized patients with COVID-19 in a New York city health system

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Letter to the Editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

The laboratory tests and host immunity of COVID-19 patients with different severity of illness

Obesity, inflammation, and the gut microbiota

Circulating mononuclear cells in the obese are in a proinflammatory state

Obesity as a risk factor for severe COVID-19: summary of the best evidence and implications for health care

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review

Association between obesity and a prothrombotic state: the Framingham Offspring Study

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Body mass index is associated with the development of acute respiratory distress syndrome

Factors associated with COVID-19-related death using OpenSAFELY

Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a Whole-Population study

Obesity, diabetes, hypertension and severe outcomes among inpatients with coronavirus disease 2019: a nationwide study

This research project was supported by the Researchers Supporting Project number (RSP-2021/340), King Saud University, Riyadh, Saudi Arabia.

The authors report no conflicts of interest in this work.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress. com/testimonials.php to read real quotes from published authors.